8-K: Oramed Announces New Phase 3 Oral Insulin Trial and Joint Venture with HTIT

Oramed is set to initiate a new Phase 3 oral insulin trial in the U.S. following positive subpopulation analysis and has formed a joint venture with HTIT, including a $90 million capital infusion.

Summary

• Oramed is moving forward with a new Phase 3 oral insulin trial in the U.S. after analyzing previous trial data and identifying patient subpopulations that responded well to the treatment.
• The company has entered into a joint venture with HTIT, a Chinese partner, to develop and commercialize oral insulin and other products, with HTIT investing $70 million and Oramed contributing $20 million.
• HTIT has successfully completed its Phase 3 trials of oral insulin in China and is in the final stages of regulatory approval, with significant investments in commercial-scale production facilities.
• Oramed holds a senior secured promissory note from Scilex with a principal balance of $101.875 million and an interest rate of SOFR plus 8.5%, secured by a lien on Scilex assets.
• Oramed has acquired rights to PeriTech's film-forming technology for topical drug delivery and has out-licensed it to an international group for royalties on net sales.

Sentiment

Score: 7

Explanation: The document presents a mix of positive developments, such as the joint venture and new trial plans, alongside some risks and challenges. The overall tone is optimistic, but the previous trial failure and the complexity of the joint venture temper the enthusiasm.

Positives

• The identification of patient subpopulations that responded well to oral insulin in previous trials allows for a more targeted approach in the new Phase 3 trial.
• The joint venture with HTIT provides significant capital and manufacturing capabilities to advance Oramed's oral drug delivery technology.
• HTIT's successful Phase 3 trial in China and investment in production facilities validate the potential of oral insulin.
• The Scilex note provides a substantial financial asset with a high interest rate and security.
• The PeriTech acquisition and out-licensing agreement offer a new revenue stream through royalties.

Negatives

• The initial Phase 3 trial in the U.S. did not meet its primary or secondary endpoints, requiring a new trial with a differentiated protocol.
• The joint venture transactions are complex and there is no guarantee that all transactions will be completed.
• There is a risk that Scilex may not be able to repay the note, potentially impacting Oramed's financial position.
• The success of the PeriTech out-licensing agreement depends on the commercial success of the licensee.

Risks

• The new Phase 3 trial may not achieve the desired results, despite the positive subpopulation analysis.
• The joint venture with HTIT may not be successful due to various factors, including regulatory hurdles and market competition.
• Scilex may default on the senior secured note, leading to potential losses for Oramed.
• The out-licensed PeriTech technology may not generate significant royalties if the products are not commercially successful.
• Oramed faces competition from other pharmaceutical and biotechnology companies.

Future Outlook

Oramed plans to initiate a new Phase 3 oral insulin trial in the U.S. later this year and is working to finalize the joint venture with HTIT, including the receipt of capital contributions. The company also expects to benefit from the commercialization of the PeriTech technology through royalty payments.

Management Comments

• Nadav Kidron, CEO, stated that Oramed is on solid ground with many opportunities to increase shareholder value.
• Kidron highlighted the successful completion of HTIT's Phase 3 trials in China and their investment in production facilities.
• Kidron expressed encouragement from the analysis of previous trial data, leading to the new Phase 3 trial protocol.
• Kidron emphasized the potential benefits of the joint venture with HTIT and the strategic out-licensing of the PeriTech technology.

Industry Context

The announcement reflects a broader industry trend towards developing oral alternatives to injectable drugs, particularly for diabetes. Oramed's focus on oral insulin delivery positions it to potentially capture a significant share of the market if successful. The joint venture with HTIT also highlights the increasing importance of partnerships with companies in China for access to manufacturing capabilities and the Chinese market.

Comparison to Industry Standards

• The development of oral insulin is a highly competitive field, with companies like Novo Nordisk and Eli Lilly also exploring similar technologies, although they have not yet achieved commercial success with an oral insulin product.
• The $90 million capital infusion into the joint venture is a significant investment, comparable to funding rounds for other biotech companies in the clinical trial phase.
• The 13.8% interest rate on the Scilex note is high, reflecting the risk associated with the borrower and the current interest rate environment.
• The out-licensing of the PeriTech technology is a common strategy in the pharmaceutical industry, allowing companies to focus on their core competencies while generating revenue from their intellectual property.

Stakeholder Impact

• Shareholders may benefit from the potential success of the new Phase 3 trial, the joint venture, and the out-licensing agreement.
• Employees may see increased job security and opportunities due to the company's growth.
• Patients may benefit from the development of an oral insulin alternative to injections.
• Suppliers and creditors may see increased business opportunities with Oramed.

Next Steps

• Initiate a Phase 3 oral insulin trial in the U.S. under a differentiated protocol.
• Finalize the joint venture agreement with HTIT and receive the capital infusion.
• Continue to explore strategies with HTIT to leverage their production capabilities.
• Monitor the repayment of the Scilex senior secured note.
• Support the commercialization of the PeriTech technology by the licensee.

Key Dates

Keywords

oral insulin, Phase 3 trial, joint venture, HTIT, drug delivery, Scilex, PeriTech, licensing, diabetes, pharmaceuticals